Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000070318
$270.63
+0.56% · live
Updated
$25.74B market value
From TENET HEALTHCARE CORP's FY2025 10-K, filed Feb 17, 2026 · read the filing
TENET HEALTHCARE provides healthcare and runs medical facilities. It took in $21.31B last year, which makes it a large company. Of every dollar it sells, about 11 cents is left as profit.
The financial picture is led by profitability and debt, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 7 insiders, not under a pre-arranged plan.
$42.4M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From TENET HEALTHCARE CORP's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$5.96B → $3.51B
Profit
$4.06B → $2.37B
Operating margin
28.8% → 16.5%
Profit margin
19.7% → 11.1%
Measured against FY2024, from the 10-K filed Feb 17, 2026
Deteriorated: -41.1%
$5.96B to $3.51BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -41.8%
$4.06B to $2.37BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
THC rose 0.56% on the latest quote. The average Health Care company tracked here moved +1.64%, and the S&P 500 −1.04%. That is 1.1 points below its sector and 1.6 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 1% a year for the next 10 years. Over the last 10 years it grew by about 30% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 11 cents of every dollar of sales as profit, earning $2.37B last year.
Slowly. Sales grew 3.1% last year.
No. At its current cash flow it could clear its debt in about 2.9 years. For every $1 it owes, it owns $1.43 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $2.37B and generated $3.54B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 17, 2026Filing for FY2025 | FY202410-K · Feb 17, 2026Filing for FY2024 | FY202310-K · Feb 17, 2026Filing for FY2023 | FY202210-K · Feb 18, 2025Filing for FY2022 | FY202110-K · Feb 18, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $21.31B | $20.68B | $20.56B | $19.17B | $19.48B | +3.1% |
| Operating income | $3.51B | $5.96B | $2.51B | $2.33B | $2.87B | −41.1% |
| Operating marginOperating income ÷ revenueWhat is this? | 16.5% | 28.8% | 12.2% | 12.2% | 14.7% | −12.3 pts |
| Interest expense | $821.0M | $826.0M | $901.0M | $890.0M | $923.0M | −0.6% |
| Income before tax | $2.80B | $5.25B | $1.62B | $1.34B | $1.89B | −46.6% |
| Net income | $2.37B | $4.06B | $1.31B | $1.00B | $1.48B | −41.8% |
| Net marginNet income ÷ revenueWhat is this? | 11.1% | 19.7% | 6.4% | 5.2% | 7.6% | −8.5 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $24.88 | $40.64 | $12.82 | $9.32 | $13.90 | −38.8% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 5,483 shares at $263.04 ($1.4M)
Holds 11,321 shares after this filing.
Sold on the open market — 4,025 shares at $264.10 ($1.1M)
Holds 7,296 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Signed a material agreement · Took on a direct financial obligation
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingWrite down why you are following TENET HEALTHCARE CORP, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 1,202 subsidiaries named in its 10-K, incorporated across 43 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from THC's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 17, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 8.7 | 6/8 | 10-K, filed Feb 17, 2026 |
| FY2024 | 7.3 | 6/8 | 10-K, filed Feb 18, 2025 |
| FY2023 | 6.0 | 8/8 | 10-K, filed Feb 16, 2024 |
| FY2022 | 3.3 | 5/8 | 10-K, filed Feb 21, 2023 |
| FY2021 | 4.7 | 7/8 | 10-K, filed Feb 18, 2022 |
| FY2020 | 3.3 | 7/8 | 10-K, filed Feb 19, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
2.24
In the grey zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −12.3 pts
28.8% to 16.5%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −8.6 pts
19.7% to 11.1%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +126.7%
$1.12B to $2.53BCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -38.8%
$40.64 to $24.88Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -4.9%
100.0M to 95.1MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: +8.5%
$931.0M to $1.01BNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 29, 2026 — read it.
Improved: +82.4%
$823.0M to $1.50BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +100.2%
$522.0M to $1.04BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +11.1 pts
15.6% to 26.7%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +8.7 pts
9.9% to 18.6%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +118.4%
$5.73 to $12.51Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -17.3%
$2.63B to $2.17BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -8.4%
91.1M to 83.5MSignificant
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Improved: +6.8%
$5.27B to $5.63BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 29, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +15.8%
$1.30B to $1.50BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +15.3%
$906.0M to $1.04BSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +19.9%
$10.44 to $12.51Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -26.9%
$2.97B to $2.17BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +2.5 pts
24.1% to 26.7%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +1.7 pts
16.9% to 18.6%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: -3.8%
86.8M to 83.5MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between -1% and 3%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 8.4x — investors pay $8.4 for each $1 of trailing profit.
This company has not reported enough of the required figures to calculate this score.
Sold on the open market — 2,502 shares at $264.62 ($662.1K)
Holds 4,794 shares after this filing.
Sold on the open market — 10,000 shares at $263.42 ($2.6M)
Holds 25,121 shares after this filing.
Sold on the open market — 1,152 shares at $258.80 ($298.1K)
Holds 23,653 shares after this filing.
Sold on the open market — 24,000 shares at $266.32 ($6.4M)
Holds 8,053 shares after this filing.
Gifted shares — 150 shares
Holds 12,403 shares after this filing.
Sold on the open market — 13,344 shares at $278.17 ($3.7M)
Holds 520,220 shares after this filing.
Sold on the open market — 36,656 shares at $278.90 ($10.2M)
Holds 483,564 shares after this filing.
Sold on the open market — 17,220 shares at $273.34 ($4.7M)
Holds 466,344 shares after this filing.
Sold on the open market — 24,881 shares at $274.10 ($6.8M)
Holds 441,463 shares after this filing.
Sold on the open market — 7,899 shares at $275.26 ($2.2M)
Holds 433,564 shares after this filing.
Sold on the open market — 1,300 shares at $278.03 ($361.4K)
Holds 12,553 shares after this filing.
Sold on the open market — 4,922 shares at $264.15 ($1.3M)
Holds 30,784 shares after this filing.
Sold on the open market — 2,500 shares at $260.83 ($652.1K)
Holds 28,284 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 12,010 shares ($3.2M) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 10,000 shares ($2.6M) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 1,152 shares ($298.1K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 24,000 shares ($6.4M) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 50,000 shares ($13.7M) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 1,300 shares ($361.4K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q2 FY2026
Revenue +6.8% · Operating margin +11.1 pts · Operating income +82.4% — against Q2 FY2025
Published results
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Operating margin +6.1 pts · Profit +45.7% · Free cash flow +127.6% — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join
Read the filingHad a director or senior officer leave or join
Read the filingAnnual report for FY2025
Operating margin −12.3 pts · Operating income -41.1% · Profit -41.8% — against FY2024
Read the filingPublished results
Read the filingPublished results · Made a Regulation FD disclosure · Reported another event
Read the filingHad a director or senior officer leave or join
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingQuarterly report for Q3 FY2025
Operating margin −4.4 pts · Operating income -18.4% · Cash -27.3% — against Q3 FY2025
Read the filingPublished results
Read the filingQuarterly report for Q2 FY2025
Earnings per share +16.8% · Shares in issue -6.3% · Operating income +8.1% — against Q2 FY2025
Read the filingThe first 40 of 1,202. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-17. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Will Tenet (THC) Beat Estimates Again in Its Next Earnings Report?
Yahoo Finance ·
Tenet Healthcare (THC) Earnings Expected to Grow: Should You Buy?
Yahoo Finance ·
Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
Yahoo Finance ·
Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know
Yahoo Finance ·
Tenet Updates Corporate Presentation and Hires The Market Link for Investor Awareness Campaign
Yahoo Finance ·
Learn Why The Bull Case For Tenet Healthcare Stock Could Change Following Guidance Raise
Yahoo Finance ·
Tenet Healthcare’s Rally Raises a Key Question About Its Valuation
Yahoo Finance ·
Why Tenet Healthcare (THC) Outpaced the Stock Market Today
Yahoo Finance ·
Tenet Healthcare, IBD's Stock Of The Day, Rides Blue Wave Toward Buy Point
Yahoo Finance ·
Tenet Healthcare (THC) Beats Stock Market Upswing: What Investors Need to Know
Yahoo Finance ·
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
Yahoo Finance ·
Tenet Upgrades Full Year 2026 Revenue Guidance Following Latest Operating Results and Developments
Yahoo Finance ·
Primary sources and further research